Orchard Therapeutics Announces Strategic Financing Totalling up to 188 Million
ORTXDelisted Stock | USD 5.27 0.01 0.19% |
Slightly above 62% of Orchard Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Orchard Therapeutics PLC suggests that many traders are alarmed regarding Orchard Therapeutics' prospects. Orchard Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Orchard Therapeutics' earnings reports, geopolitical events, and overall market trends.
Orchard |
Proceeds to accelerate commercialization of Libmeldy and advance the companys HSC gene therapy RD portfolio Initial closing of 34 million to...
Read at globenewswire.com
Orchard Therapeutics Fundamental Analysis
We analyze Orchard Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orchard Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orchard Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Orchard Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Orchard Therapeutics PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Orchard Therapeutics stock to make a market-neutral strategy. Peer analysis of Orchard Therapeutics could also be used in its relative valuation, which is a method of valuing Orchard Therapeutics by comparing valuation metrics with similar companies.
Peers
Orchard Therapeutics Related Equities
ELDN | Eledon Pharmaceuticals | 8.92 | ||||
PDSB | PDS Biotechnology | 4.65 | ||||
TERN | Terns Pharmaceuticals | 3.41 | ||||
HOOK | Hookipa Pharma | 1.16 | ||||
DAWN | Day One | 1.81 | ||||
ABOS | Acumen Pharmaceuticals | 2.98 | ||||
AMLX | Amylyx Pharmaceuticals | 3.60 | ||||
XFOR | X4 Pharmaceuticals | 5.13 | ||||
INZY | Inozyme Pharma | 6.09 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Orchard Stock
If you are still planning to invest in Orchard Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orchard Therapeutics' history and understand the potential risks before investing.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
CEOs Directory Screen CEOs from public companies around the world | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |